Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2009 - 2018)

Alnylam Pharmaceuticals (ALNY) has reported Depreciation & Amortization (CF) for 10 consecutive years, with $3.2 million the latest figure, recorded in Q1 2018.

• For the quarter ending Q1 2018, Depreciation & Amortization (CF) rose 5.93% year-over-year to $3.2 million; the trailing twelve-month figure through Dec 2018 stood at $3.2 million (down 76.23% YoY), and the FY2017 full-year result was $13.4 million, down 11.65% from the prior year.
• Depreciation & Amortization (CF) fell to $3.2 million in Q1 2018 per ALNY's latest filing, from $3.7 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $5.3 million in Q3 2015 and bottomed at $2.6 million in Q1 2014.
• Historically, Depreciation & Amortization (CF) has averaged $3.7 million across 5 years, with a median of $3.5 million in 2016.
• The sharpest annual moves came in 2015 and 2016: Depreciation & Amortization (CF) soared 75.07% in 2015, then slumped 40.46% in 2016.
• Over 5 years, Depreciation & Amortization (CF) stood at $3.3 million in 2014, then soared by 51.72% to $5.1 million in 2015, then plunged by 40.46% to $3.0 million in 2016, then grew by 23.06% to $3.7 million in 2017, then declined by 14.43% to $3.2 million in 2018.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $3.2 million, $3.7 million, and $3.6 million for Q1 2018, Q4 2017, and Q3 2017 respectively.